Quintrio
Home

MEDICINAL CHEMICALS & BOTANICAL PRODUCTS

Trulieve Cannabis Corp.

TRLV

Trulieve Cannabis Corp is a vertically integrated cannabis company that grows, produces, and sells cannabis products. It has licenses to operate in Arizona, Colorado, Connecticut, Florida, Georgia, Maryland, Ohio, Pennsylvania, and West Virginia, where it sells medical cannabis products. In addition, the company sells cannabis products for adult use in Arizona, Colorado, Connecticut, Maryland, and Ohio. The firm's operations are substantially located in Florida and, to a lesser extent, in Arizona and Pennsylvania.

Last trade $10.19
Day change -$0.1375 (-1.33%)
Day range $9.89 – $10.72
Volume 886,568
Market cap $1.76B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.76B
Price / earnings
—
Price / book
2.28×
Price / sales
1.63×
EV / sales
1.48×
EV / EBITDA
5.55×

Profitability

Earnings per share
-$2.61
Return on assets
-21.04%
Return on equity
-57.63%
Dividend yield
0.55%

Liquidity and leverage

Debt / equity
0.21×
Current ratio
5.52×
Quick ratio
3.65×
Cash ratio
3.2×

Cash flow

Price / cash flow
7.27×
Price / free cash flow
11.07×
Free cash flow
$159.24M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TRLV, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026
Revenue$230.22M$270.95M
Cost of revenue$82.2M$108.66M
Gross profit$148.02M$162.29M
Selling, general and administrative$87.85M$101.77M
Research and development$0$0
Total operating expenses$105.53M$532.81M
Operating income$42.49M-$370.52M
Interest expense-$11.98M-$12.76M
Income before taxes$27.03M-$383.4M
Income taxes$26.25M$21.97M
Net income$774K-$406.06M
Net income attributable to common shareholders$869K-$405.98M
EBITDA$72.43M$73.95M
Basic earnings per share$0.00-$2.10
Diluted earnings per share$0.00-$2.10

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Green Thumb Ended Its String of Profitable Quarters. Is the Stock a Buy?

Green Thumb Industries reported its first quarterly loss since Q2 2025, ending a four-quarter profitable streak. However, the company continues to show strong fundamentals with 11.3% year-over-year revenue growth to $324.4 million, solid operating cash flow of $58 million, and aggressive share buybacks of 13.4 million shares. The loss is attributed to expansion efforts, including opening six new RISE dispensaries. The company is well-positioned for future growth with upcoming legalization in Virginia and expansion opportunities in key states.

Zacks Investment Research

Zacks Industry Outlook Highlights ICU Medical, Neogen and Trulieve Cannabis

The Medical Products industry faces moderate growth prospects with resilient healthcare demand offset by tariff pressures and manufacturing costs. ICU Medical shows strong momentum in infusion systems with improving earnings, Neogen benefits from commercial execution improvements in food and animal safety, while Trulieve Cannabis expects growth acceleration from new markets like Georgia and Texas despite Florida seasonal softness.

The Motley Fool

2 Cannabis Stocks That Are Quietly Trouncing the Market in 2026

Trulieve Cannabis and Cronos Group have both gained approximately 27% in 2026, outpacing the S&P 500's 12% gain. Trulieve, now listed on the NYSE, generated $74 million in free cash flow in H1 2026 with a 60% gross margin. Cronos delivered 58% year-over-year revenue growth to $53 million in Q2 with expanding margins and $827 million in cash, while also returning capital to shareholders through share buybacks.

The Motley Fool

The First U.S. Marijuana Stock Is Now Trading on the NYSE. Here's What That Means for Every Cannabis Investor.

Trulieve Cannabis became the first U.S. cannabis operator to list on the NYSE after the federal government reclassified medical marijuana to Schedule III. This milestone could open doors for institutional investors and improve market access for the cannabis industry, though significant challenges including debt, market saturation, and regulatory uncertainty remain.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.